Prescient Therapeutics Ltd
PTX
Company Profile
Business description
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Contact
Level 4, 100 Albert Road
South Melbourne
MelbourneVIC3205
AUST: +61 396927222
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
12
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,753.30 | 4.60 | -0.05% |
| CAC 40 | 7,656.12 | 27.61 | -0.36% |
| DAX 40 | 23,317.81 | 116.84 | -0.50% |
| Dow JONES (US) | 42,171.66 | 44.14 | -0.10% |
| FTSE 100 | 8,843.47 | 9.44 | 0.11% |
| HKSE | 23,231.48 | 479.21 | -2.02% |
| NASDAQ | 19,546.27 | 25.18 | 0.13% |
| Nikkei 225 | 38,579.80 | 305.35 | -0.79% |
| NZX 50 Index | 12,582.49 | 44.83 | -0.36% |
| S&P 500 | 5,980.87 | 1.85 | -0.03% |
| S&P/ASX 200 | 8,535.90 | 4.70 | 0.06% |
| SSE Composite Index | 3,359.78 | 29.03 | -0.86% |